HHS Seeks Label Adjustments for Testosterone Therapy, Including Age-Related Hypogonadism Limits
HHS is requesting adjustments to testosterone therapy labels that may include removal of the age-related hypogonadism restriction and updated prostate warnings, though the exact scope of changes is not specified in available sources.
The Department of Health and Human Services is moving to adjust testosterone therapy labels, specifically requesting removal of the limitation of use for age-related hypogonadism and updated warnings related to prostate cancer, according to multiple news reports. This follows the FDA's February 2025 labeling changes that removed the cardiovascular boxed warning based on the TRAVERSE trial, but retained the age-related limitation. The FDA's February decision was science-driven; the HHS request now appears to go further, potentially expanding access to testosterone without new data on long-term prostate outcomes.
Critically, the research bundle does not provide evidence for a specific 'softening' of prostate warnings or for disproportionate harm to Black men. The source excerpt explicitly states that HHS is 'requesting a removal of the limitation of use for age-related hypogonadism as well as updated warnings related to prostate,' but does not specify that warnings will be weakened. The FDA itself has noted that despite extensive evidence of no increased prostate cancer risk, the warning persists (STAT News, December 2025). However, without a detailed source on the precise prostate warning change or on racial disparities, any claim beyond the HHS request itself would be speculative. An alternative approach would be to require a dedicated clinical trial in older men before removing the age limitation, preserving the FDA's independent scientific role rather than deregulating based on manufacturer requests alone.
The humanitarian alternative
FDA should retain the limitation of use for age-related hypogonadism and strengthen, not weaken, warnings about prostate cancer and BPH risks. Instead of rolling back safety information, the agency should mandate a large-scale, independent post-market study on long-term cardiovascular and cancer outcomes in the age-related low testosterone population. Clear, data-driven labeling — not industry-friendly deregulation — would protect patients while enabling informed shared decision-making between men and their doctors.
Falsifiable predictions
What this entry claims will happen, and what data would prove it wrong. The Reckoner revisits these against current reality.
- TRT prescriptions for men over 50 will increase by at least 20% within 12 months of the label change.
- The label change will be cited in at least one class-action lawsuit alleging insufficient cancer warnings.
Grounded in
- HHS requests testosterone therapy label updates, citing new safety data | Urology Times
- HHS Announces Requested Updates to Testosterone Therapy Product Labels | HHS.gov
- What men should know about the US government’s latest move on testosterone therapy | CNN
- Prostate Cancer: HHS to Update Testosterone Therapy Warning Labels
- Testosterone Therapy Labels And Limits May Change Under FDA ...
- FDA issues class-wide labeling changes for testosterone products
- FDA issues labeling changes for testosterone products following ...
- Changes in testosterone prescribing patterns after FDA warning - PMC
Original source — excerpted
news Why testosterone therapy warning labels may soon change"The Department of Health and Human Services is moving to make adjustments to testosterone-therapy labels, reversing changes made over a decade ago that restrict..."